Neurocrine CLO sells 10,000 shares after option exercise
Neurocrine Biosciences Chief Legal Officer Darin Lippoldt exercised stock options for 10,000 shares of common stock and sold 10,000 shares in open-market transactions.
Rhea-AI Filing Summary
Neurocrine Biosciences Chief Legal Officer Darin Lippoldt exercised stock options for 10,000 shares of common stock and sold 10,000 shares in open-market transactions. The options had an exercise price of $81.49 per share, while the reported sales occurred around $169.57–$170.91 per share on June 26 and June 29, 2026.
The filing shows this as an exercise-and-sell pattern, converting option value into cash rather than increasing net share ownership. After these transactions, Lippoldt directly holds 54,729 shares of Neurocrine Biosciences common stock and retains additional non-qualified stock options. The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on June 9, 2025.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 10,000 shares ($887K approx. pre-tax spread)
Exercise and Sale
9 txns
Insider
Lippoldt Darin
Role
Chief Legal Officer
Sold
10,000 shs ($1.70M)
Approx. gross sale proceeds
$1.70M
Approx. exercise cost
$815K
Approx. pre-tax spread
$887K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Non-Qualified Stock Option | 8,110 | $0.00 | $0.00 |
| Exercise | Non-Qualified Stock Option | 1,690 | $0.00 | $0.00 |
| Exercise | Common Stock | 8,110 | $81.49 | $661K |
| Sale | Common Stock | 8,110 | $170.025 | $1.38M |
| Exercise | Common Stock | 1,690 | $81.49 | $138K |
| Sale | Common Stock | 1,690 | $170.8144 | $289K |
| Exercise | Non-Qualified Stock Option | 200 | $0.00 | $0.00 |
| Exercise | Common Stock | 200 | $81.49 | $16K |
| Sale | Common Stock | 200 | $169.565 | $34K |
Holdings After Transaction:
Non-Qualified Stock Option — 14,965 contracts (Direct);
Common Stock — 54,729 shares (Direct)
Footnotes (5)
- F1. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 9, 2025. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
- F2. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $169.56 to $169.57. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F3. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $169.57 to $170.56. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F4. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $170.58 to $170.91. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F5. The option was granted February 5, 2018 and vested in 48 equal monthly installments beginning March 5, 2018.
Key Figures
Shares sold: 10,000 shares
Option exercise price: $81.49 per share
Sale price example: $170.8144 per share
+3 more
6 metrics
Shares sold
10,000 shares
Total NBIX common shares sold in open-market transactions on June 26 and June 29, 2026
Option exercise price
$81.49 per share
Exercise price of non-qualified stock options converted into common stock
Sale price example
$170.8144 per share
Weighted average price for a 1,690-share sale of NBIX common stock
Post-transaction holdings
54,729 shares
NBIX common shares directly owned by Lippoldt after reported transactions
Option expiration
February 5, 2028
Expiration date for reported non-qualified stock options after partial exercise
Option exercises
10,000 shares
Total common shares acquired through option exercises in this filing
Key Terms
Rule 10b5-1 trading plan, Non-Qualified Stock Option, weighted average sales price per share, vested in 48 equal monthly installments, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"The disposition reported ... was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted..."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
Non-Qualified Stock Option financial
"security_title: "Non-Qualified Stock Option" with underlying security title "Common Stock""
A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.
vested in 48 equal monthly installments financial
"The option was granted February 5, 2018 and vested in 48 equal monthly installments beginning March 5, 2018."
open-market sale financial
"transaction_action: "open-market sale" for common stock dispositions coded "S""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
FAQ
What insider transaction did NBIX Chief Legal Officer Darin Lippoldt report?
Darin Lippoldt reported exercising options for 10,000 NBIX shares at $81.49 and selling 10,000 shares in the open market. This turned option value into cash without increasing his net common-share holdings.
Were Darin Lippoldt’s NBIX stock sales made under a Rule 10b5-1 plan?
Yes. A footnote explains the dispositions were executed by a broker under a Rule 10b5-1 trading plan adopted on June 9, 2025. The company’s policy restricts him from amending or modifying such a plan after adoption.
What were the terms of the NBIX stock options Darin Lippoldt exercised?
The exercised non-qualified stock options had a conversion or exercise price of $81.49 per share and were originally granted on February 5, 2018. A footnote states they vested in 48 equal monthly installments beginning March 5, 2018.
AI-generated analysis. How Rhea-AI works. Not financial advice.
